About Vernalis plc
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders. The Company markets three products, including Tuzistra XR in the United States prescription cough cold market; Moxatag, which is a once daily amoxicillin approved in the United States for tonsillitis and pharyngitis, and frovatriptan, which is an acute treatment for migraine. The Company also has four over prescription cough cold products under development and a pipeline of new chemical entity (NCE) development programs and research collaborations.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Exchange: LON
- Symbol: VER
- Previous Close: $0.32
- 50 Day Moving Average: $31.46
- 200 Day Moving Average: $37.13
- 52-Week Range: GBX 25.31 - GBX 65
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Market Cap: $134.18M
- Outstanding Shares: 526,196,000
Earnings History for Vernalis plc (LON:VER)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Vernalis plc (LON:VER)
Current Year EPS Consensus Estimate: $-5.57 EPS
Dividend History for Vernalis plc (LON:VER)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Vernalis plc (LON:VER)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/12/2016||David Mackney||Insider||Sell||27,233||GBX 39||£10,620.87|
|9/30/2016||Carol Ferguson||Insider||Buy||28,000||GBX 41||£11,480|
|5/5/2015||Nigel Sheail||Insider||Buy||84,000||GBX 59.90||£50,316|
Latest Headlines for Vernalis plc (LON:VER)
What is Vernalis plc's stock symbol?
Vernalis plc trades on the London Stock Exchange (LON) under the ticker symbol "VER."
Where is Vernalis plc's stock going? Where will Vernalis plc's stock price be in 2017?
4 equities research analysts have issued 12 month price objectives for Vernalis plc's shares. Their predictions range from GBX 37 to GBX 104. On average, they expect Vernalis plc's share price to reach GBX 73.50 in the next year.
When will Vernalis plc announce their earnings?
Vernalis plc is scheduled to release their next quarterly earnings announcement on Wednesday, March, 15th 2017.
How do I buy Vernalis plc stock?
Shares of Vernalis plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
How much does a share of Vernalis plc stock cost?
One share of Vernalis plc stock can currently be purchased for approximately GBX 25.50.